Pfizer’s Board of Directors, in a meeting held from February 20 to February 21, 2025, approved a strategic Marketing and Supply Agreement with Mylan Pharmaceuticals Private Limited. The agreement focuses on the domestic marketing and sale of Pfizer’s two renowned brands, Ativan and Pacitane, within India for a period of five years.
This collaboration leverages Mylan’s strong presence in the Central Nervous System (CNS) therapy segment, backed by its skilled resources and expertise in engaging with neurologists and psychiatrists. By partnering with Mylan, Pfizer aims to enhance the distribution network and in-clinic presence of Ativan and Pacitane, ensuring broader accessibility for patients across India.
In the exchange filing, the company shared, “The Board of Directors of the company at their Meeting held today, that commenced on February 20, 2025 at 11.00 a.m. and concluded on February 21, 2025 at 1.45 p.m have approved a proposal today, to enter into a Marketing and Supply Agreement with Mylan Pharmaceuticals Private Limited (“Mylan”) for Marketing and Sale of two brands of the Company, viz., Ativan and Pacitane.”
The agreement does not involve any share exchange or joint venture and is not classified as a related party transaction. Both companies will operate on commercial terms mutually agreed upon, ensuring a fair and arm’s-length partnership. This strategic move is expected to strengthen Pfizer’s market position in India’s CNS therapy segment while providing patients with improved access to essential medications.
